TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · Real-Time Price · USD

14.15

+1.93 (15.79%)

Oct 8, 2025, 12:06 PM EDT - Market open

TransCode Therapeutics Employees

TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.

Employees

7

Change (1Y)

-3

Growth (1Y)

-30.00%

Revenue / Employee

n/a

Profits / Employee

-$3,514,180

Market Cap

11.80M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	7	-3	-30.00%
Dec 31, 2023	10	-9	-47.37%
Dec 31, 2022	19	10	111.11%
Dec 31, 2021	9	3	50.00%
Dec 31, 2020	6	0	-
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

RNAZ News

4 months ago - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - PRNewsWire
5 months ago - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - PRNewsWire
5 months ago - TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PRNewsWire
5 months ago - TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - PRNewsWire
5 months ago - TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer - PRNewsWire
6 months ago - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - PRNewsWire
6 months ago - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 - PRNewsWire
7 months ago - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering - PRNewsWire